- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01261507
Reader Study of DeltaView™ Chest Radiograph Software
November 4, 2015 updated by: Matthew T. Freedman, MD, Georgetown University
Reader Study to Demonstrate That Use of DeltaView™ is Superior to the Use Standard Prior and Current Antero/Posterior (AP/PA) X-ray Image Pair
A new software product takes two chest radiographs, aligns them, and then subtracts one image from the other.
The resulting image represents an image showing any differences between them.
The study is to determine whether radiologists using this new software perform better with it than when they do not use it.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
15
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- ISIS Research Center, Georgetown University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Radiologists in community practice of radiology chest radiographs of individuals with or without a lung nodule
Description
Inclusion Criteria:
For Radiologists: American Board of Radiology Certification and live within the Baltimore, MD-Washington, DC Metropolitan areas
For chest radiographs, evidence of the presence or absence of lung nodule confirmed by expert panel; adequate image quality
-
Exclusion Criteria:
Radiologists who assisted by providing cases for review
For chest radiographs: poor image quality
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Localized Receiver Operating Characteristic (LROC) Comparison
Time Frame: 1 day
|
The area under the LROC curve will be compared for the chest radiograph interpretations done without the new software and those done with the new software.
Improvement will be demonstrated if the improvement with the new software is statistically significant at the p=<0.05.
There were 422 cases in the total study.
20 of these were inserted as "noise" cases, not to be analyzed.
Thus there were 402 cases to be analyzed.
There were 120 cases with nodules and 282 without a nodule.
LROC is a method for measuring the success or failure of a method where there is a tradeoff between the detection of lung nodules that are there (true positives) and the detection that the radiologist considers to be a nodule where no nodule is present (false positive).
It yields a single number that done not have a unit of measurement.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity and Specificity
Time Frame: 1 day
|
Sensitivity and specificity will be measured.
If the radiologists using the new software have higher sensitivity, statistically significant at the p=< 0.05, the use of the new software will be considered to have resulted in improvement.
A decrease in specificity is expected.
|
1 day
|
|
False Positive Decisions of Radiologists
Time Frame: 1 day
|
This is a comparison of the radiologists working without and with the software.
The false positive rate is the percentage of cases in which the radiologists identified a lesions/location suspected of being cancer at a location where cancer was not present. .
A false positive represents a location selected on a chest image without cancer and, also, a mark on a chest image where cancer was present, but a different location, one without cancer, was marked.The radiologists could mark up to five locations on an image and had to provide a confidence rating for each.
This analysis is of the single mark with the highest confidence level.
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Matthew T Freedman, MD, MBA, Georgetown University
- Principal Investigator: S.-C. Ben Lo, PhD, Georgetown University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
December 14, 2010
First Submitted That Met QC Criteria
December 15, 2010
First Posted (Estimate)
December 16, 2010
Study Record Updates
Last Update Posted (Estimate)
December 1, 2015
Last Update Submitted That Met QC Criteria
November 4, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DHF-183-0531A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Neoplasm
-
National Cancer Institute (NCI)RecruitingLocally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditionsUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedPrimary Malignant Neoplasm of Lung | Primary Malignant Neoplasm of Gastrointestinal TractUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung Carcinoma | Lung Neoplasm | Malignant Lung NeoplasmUnited States
-
Bavarian Cancer RegistryBavarian Association of Statutory Health Insurance Accredited PhysiciansRecruitingNeuroendocrine Neoplasm of Lung | Neuroendocrine Neoplasm of Gastrointestinal Tract (Disorder)Germany
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
Jiangsu ShengDiYa Medicine Co., Ltd.Dongguan People's HospitalUnknownNonsquamous Nonsmall Cell Neoplasm of Lung
-
Spanish Lung Cancer GroupCompletedNonsquamous Nonsmall Cell Neoplasm of LungSpain
-
Rgene CorporationAmerican BriVision CorporationNot yet recruitingNonsquamous Nonsmall Cell Neoplasm of LungTaiwan
-
OncoMed Pharmaceuticals, Inc.Celgene CorporationCompletedNonsquamous Nonsmall Cell Neoplasm of LungSpain, United States, Australia, Italy, Belgium